. developed an initial study plan and refined this plan with insights from R.J.S., J.R., A.P., E.H.W. and P.J.M. Patient collections including DNA samples were established and/or further developed by
Transplantation and pregnancy, in which two diploid genomes reside in one body, can each lead to diseases in which immune cells from one individual target antigens encoded in the other's genome. One such disease, graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT, or bone marrow transplant), is common even after transplants between HLA-identical siblings, indicating that cryptic histocompatibility loci exist outside the HLA locus. The immune system of an individual whose genome is homozygous for a gene deletion could recognize epitopes encoded by that gene as alloantigens. Analyzing common gene deletions in three HSCT cohorts (1,345 HLA-identical sibling donorrecipient pairs), we found that risk of acute GVHD was greater (odds ratio (OR) = 2.5; 95% confidence interval (CI) 1.4-4.6) when donor and recipient were mismatched for homozygous deletion of UGT2B17, a gene expressed in GVHD-affected tissues and giving rise to multiple histocompatibility antigens. Human genome structural variation merits investigation as a potential mechanism in diseases of alloimmunity.
GVHD is a serious, common complication of allogeneic HSCT (or bone marrow transplant) in which immune responses by donorderived lymphocytes target alloantigens in the host. GVHD rarely occurs after transplants between monozygotic twins 1,2 but frequently occurs after transplants between HLA-identical siblings, indicating that additional histocompatibility loci must exist outside the HLA locus.
One clear example of a non-HLA compatibility locus is the Y chromosome, in that there is increased risk of GVHD when HSCT involves a female donor and a male recipient 3 . This effect arises from immune recognition (by donor-derived lymphocytes and antibodies) of antigens encoded by a few Y-linked genes that are expressed in the soma [4] [5] [6] [7] [8] [9] . These genes collectively differ in sequence from their X-linked paralogs at only a few hundred amino acids 10 . This observation demonstrates that changes in an individual's antigen repertoire of hundreds of amino acids, the size of many individual autosomal genes, can increase risk of GVHD.
The human genome is increasingly recognized to have extensive structural polymorphism 11, 12 , including deletions of entire autosomal genes 13, 14 . Some of these gene-deletion alleles are sufficiently common that individuals inherit them from both parents and therefore completely lack a protein-coding gene that is expressed in other individuals 13 . Because the immune system of an individual with a homozygous gene deletion presumably has not learned to tolerate the protein encoded by that gene, immune recognition of that protein as an alloantigen 15, 16 by immune cells or antibodies from that individual could in principle contribute to risk of alloimmune disease.
To assess whether donor-recipient mismatch for homozygous gene deletions increases the risk of GVHD after transplantation, we first typed a set of common gene deletions in 414 HSCT patients and their HLA-identical sibling donors (cohort A; Online Methods, Table 1 ). This screen involved gene-deletion polymorphisms that we identified from a genome-wide survey of copy number variation 17 as satisfying the following criteria: a deletion allele that (i) removes the gene protein-coding sequence and (ii) segregates in the population with allele frequency >10%; (iii) expression of the gene in one or more of the tissues commonly involved in acute GVHD (liver, intestine, skin); and (iv) significant sequence difference (tens to hundreds of amino acids) from any paralogous gene encoded elsewhere in the human genome ( Table 2 ). The following genes were identified from this screen: UGT2B17, UGT2B28, GSTM1, GSTT1, LCE3C and OR51A2. We assessed association with GVHD risk by first typing each deletion in HSCT patients and their sibling donors so as to determine which transplants involved homozygous gene deletion in the donor but not the recipient (Supplementary Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease 1 3 4 2 volume 41 | number 12 | december 2009 Nature GeNetics l e t t e r s Note). At each locus we then assessed whether such mismatches were associated with increased risk of acute GVHD (Fig. 1a) .
In this initial screen, donor-recipient mismatch for homozygous deletion of one of these genes, UGT2B17, showed a promising potential association with GVHD ( Fig. 1a ; OR = 3.0, 95% CI 1.3-6.9, nominal P = 0.006, by Cochran-Mantel-Haenszel test; 0.03 after Bonferroni correction). UGT2B17 encodes a cell-surface protein comprising 530 amino acids that is highly expressed in the same tissues-liver, intestine and skin-that are affected by clinically apparent GVHD and targeted by donor-derived lymphocytes. For the other five gene deletions tested, we observed no evidence of association of donorrecipient mismatch with acute GVHD (Fig. 1a) .
We further assessed the contribution of UGT2B17 mismatches to GVHD in two additional patient cohorts (cohorts B and C, Table 1 ).
Outcomes in cohorts B and C also involved an increased risk in transplants involving donor-recipient mismatch at UGT2B17 (OR = 2.4, 95% CI 1.1-5.1, P = 0.02, by CochranMantel-Haenszel test), strengthening the overall evidence for association (Fig. 1b We evaluated alternative models for the association of GVHD with donor-recipient mismatch at UGT2B17. In particular, the observed association might in principle be due to donor genotype or patient genotype independent of donor-recipient mismatch, particularly given that variation at UGT2B17 associates to other clinical phenotypes [18] [19] [20] . We therefore evaluated the data from all 1,345 donor-recipient pairs in cohorts A, B and C (Cochran-Mantel-Haenszel test) to assess the risk of GVHD for each combination of donor and recipient UGT2B17 status, relative to a reference group in which donor and recipient were both UGT2B17 positive (Fig. 1c) . Increased risk was confined to the group of transplants for which donors were UGT2B17 negative and recipients were UGT2B17 positive (Fig. 1c) . In particular, the UGT2B17 status of the hematopoietic stem cell (HSC) donor was not associated with GVHD when HSC recipients were UGT2B17 negative, and the UGT2B17 status of the HSC recipient was not associated with GVHD when HSC donors were UGT2B17 positive (Fig. 1c) .
To assess the time course of GVHD incidence in patients with UGT2B17-mismatched donors, a cumulative incidence analysis was performed (Fig. 2) . UGT2B17-positive patients with UGT2B17-negative donors showed an unremarkable incidence of acute GVHD during the first 20 d after transplantation; GVHD then began to increase beyond the level observed in other patients after day 20, a pattern similar to that observed in male patients who receive transplants from female donors.
A corollary of the model in which common gene deletions contribute to GVHD risk is that immune responses to multiple antigens derived from UGT2B17 would be present in patients. Several years ago a cytotoxic T-cell clone derived from a patient with acute GVHD of the intestine was used to screen an expression library to identify the antigen recognized by the T cell; the antigen was determined to be AELLNIPFLY, a peptide derived from UGT2B17 and presented by HLA-A*2902 in this patient 16 . AELLNIPFLY was subsequently found to be presented also by Note that the ratio of affected to unaffected individuals is not uniform across cohorts, primarily because the criteria for patient selection differed from institution to institution. These selection criteria were defined before genetic analysis and for cohorts B and C reflected the design of earlier studies. Cohort C used a cohort design, whereas cohort B used a case-control design and oversampled patients with severe acute GVHD to maximize power. Diagnostic sensitivity in the grading of GVHD can also differ among clinical institutions 29 , although it is generally well harmonized within institutions. 
l e t t e r s
HLA-B*4403 and recognized in this form by a distinct T-cell clone from the same patient 21 . Screening of a cytotoxic T-cell clone from a different patient recently identified CVATMIFMI, a different UGT2B17-derived peptide, as the antigen recognized by the clone, when presented by the common HLA allele HLA-A*0206 (ref. 22) . Given evidence that antibody responses can also contribute to GVHD [23] [24] [25] [26] , and the possibility that UGT2B17's predicted localization to the cell surface would facilitate such responses, we screened sera from 26 GVHD patients (including ten with UGT2B17-mismatched donors) against an array of overlapping peptides designed to span the UGT2B17 protein sequence. Serum from one patient (a UGT2B17-positive patient whose donor was UGT2B17 negative) showed a robust antibody response to the peptide LQESKFDVLLADAVNPCGEL (UGT2B17 141-160 ); we fine mapped this response to the epitope VLLADAVNP (UGT2B17 148-156 ). Antibodies from this patient distinguished this epitope from paralogous peptide sequences encoded by all other UGT2B genes in the human genome. These data collectively indicate that UGT2B17 gives rise to multiple histocompatibility antigens (Fig. 3) , offering a candidate molecular and cellular mechanism for genetic association of UGT2B17 mismatch with GVHD. Several features of the UGT2B17 protein may make UGT2B17 a more potent histocompatibility locus than other gene deletions: (i) UGT2B17 is a large protein (530 amino acids), increasing the likelihood that it contains multiple antigenic epitopes; (ii) UGT2B17 is abundant in liver, intestine and skin, the tissues in which pre-HSCT conditioning elicits the strongest inflammation and in which immune surveillance for alloantigens may therefore be strongest; (iii) UGT2B17 is expressed on the cell surface, well positioned to contribute to antibody-mediated as well as cell-mediated immune responses; and (iv) UGT2B17 is also abundant in blood, skin, semen and placenta, tissues that give rise to interindividual immune exposures that may pre-expose and immunize UGT2B17-negative individuals against UGT2B17, a phenomenon that has been observed in healthy female donors for some of the antigens encoded on the Y chromosome 23 .
Although an estimate of effect size for donor-recipient UGT2B17 mismatches in GVHD based on the cohorts analyzed here (OR = 2.5) is comparable to the established effect of sex mismatch (female donor, male recipient), UGT2B17 mismatches cannot explain a comparable fraction of GVHD incidence because of the lower frequency at which UGT2B17 mismatches arise between siblings. This sibling mismatch frequency varies among populations as a result of population variation in frequency of the UGT2B17-deletion allele (19-85%, an unusually high level of variation that has been attributed to adaptive evolution of UGT2B17 copy number 27 ); as a result, the expected frequency of sibling mismatches ranges from 2% in African Americans to 5% in most European populations to 9% in Gujarati Indians but does not approach the frequency of female-to-male sex mismatch (25%) in any population (Supplementary Table 2 ). We also caution that the association observed here should be considered preliminary until confirmed by independent, multicenter investigations, and that it may not extend to transplants involving unrelated donors 19 , for which the potent effects of donor-recipient mismatches at untyped HLA loci 28 may dominate the effects of mismatches outside the HLA.
The gene-deletion polymorphisms analyzed here could in principle be a leading edge of a larger class of polymorphisms that have many and varied effects on antigen repertoire. Such polymorphisms might include not only deletion alleles but SNPs that introduce early stop codons and frameshifts into protein-coding sequences, alleles that alter transcript splicing, and null regulatory alleles. As large-scale sequence data increasingly make it possible to catalog all the singlenucleotide and structural polymorphisms that segregate in human populations, it will be important to identify the polymorphisms that have multifold effects on antigen repertoire. Human genome structural variation has been proposed to affect phenotypes by altering gene dosage and by affecting the regulation of nearby genes. Structural polymorphism may also influence disease by a very different mechanism-by giving rise to multifold differences between individuals' antigen repertoires that arise from specific genomic loci. The generality of such relationships-in other transplantation settings and in pregnancy-will be an important subject of investigation.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
